History & Overview Annual Report President's Pages Center News Community Affairs
Make a Gift Yankees Universe Fund Fred's Team Donating Blood & Platelets Volunteering Thrift Shop Park Avenue Potluck Cookbook
Press Releases Information for Journalists News@MSKCC
Manhattan New Jersey Long Island Westchester
Working at Memorial Sloan-Kettering Work Sites College Recruitment About Nursing Job Fairs & Career Days Job Search & Apply Online
Making an Appointment

Memorial Sloan-Kettering Cancer Center has the nation's most extensive experience with bone cancer, treating more of these tumors than any other institution in the United States. Moreover, each patient's care is delivered in a way that ensures optimal quality of life, preserving form and function whenever possible.

Our doctors created the first detailed descriptions of osteosarcoma, as well as Ewing's sarcoma. In fact, Dr. James Ewing, who first described the disease, was the original leader of Memorial Hospital and the scientific founder of Memorial Sloan-Kettering Cancer Center. Today, physicians around the world share the knowledge gained by Memorial Sloan-Kettering's doctors, and are helping their patients with bone cancer live longer and better with treatments and surgical techniques that have been pioneered here.

Team Approach to Care

The number of patients with primary bone cancer seen at Memorial Sloan-Kettering -- about 175 a year -- gives our physicians the expertise to recognize and treat rare forms of the disease and the ability to quickly identify, manage, and avoid treatment complications. Our doctors also see more than 500 patients a year with metastatic cancers to bone (cancers that have spread to the bone from other sites).

Our Publications
Our Publications
Visit PubMed for our journal articles

As with all types of cancer, Memorial Sloan-Kettering takes a multidisciplinary approach to bone cancer. A 14-physician Primary Bone Disease Management Team -- including surgeons, medical oncologists, radiologists, radiation oncologists, and pathologists -- meet weekly and work closely together to create treatment regimens, monitor the patient's progress, and select and modify therapies. Our team also includes pediatric oncologists with special expertise in bone tumors and sarcomas of childhood.

Our experience extends to patients who develop Paget's disease, fibrous dysplasia, and osteochondromotosis, or who develop sarcomas in difficult-to-treat locations such as the pelvis. We also offer a combined neurosurgery-orthopaedic team specializing in spinal bone cancers and expertise in sarcoma of the hand.

The Leading Edge of Surgical Expertise

Surgeons at Memorial Sloan-Kettering are able to save the affected limb (arm or leg) in most bone cancer surgeries, and have developed replacements that are more durable and functional. Our surgeons were the first to perform successful limb-salvage surgery for patients with high-grade bone sarcomas.

When an entire leg cannot be saved, surgeons keep as much as possible so that they can reconstruct the most functional limb possible. An example is a procedure called van Nes rotationplasty that recreates a functioning knee that can withstand vigorous athletic activity. Memorial Sloan-Kettering physicians led studies to create longer-lasting prostheses, such as the CompreSs implant -- a novel method to secure a knee replacement to the thigh bone. We are also using specially designed expandable prostheses in children that "grow" as a child grows, so that a second surgery can usually be avoided later in life.

Cryosurgery (freezing and killing of cancer cells) is sometimes used in addition to surgery in certain patients with bone cancer. Memorial Sloan-Kettering surgeons were the first to use cryosurgery, perfecting its use to reduce tumor recurrence while preserving limb and joint function. After a bone tumor is removed, liquid nitrogen is used to freeze the tumor cavity to subzero temperatures, killing microscopic tumor cells. Cryosurgery decreases the chance of tumor recurrence and may also lessen the need for amputation.

Advanced Imaging Technology

An important part of the diagnosis and follow-up screening of bone cancer is imaging. During the diagnosis phase, our radiologists will usually start by ordering imaging tests such as an x-ray, which will allow the doctor to see any unusual bone growths. This may be followed by a bone scan, to see if there are other abnormal areas in the skeleton. A CT (computed tomography) or MRI (magnetic resonance imaging) scan is often ordered to show the exact size and shape of the suspected bone tumor, and to determine if it has invaded surrounding tissue or the bone marrow space. A PET (positron emission tomography) scan is also used to diagnose bone cancer and is especially useful when identifying metastasis. PET and CT scans can be used in combination to pinpoint the exact location of cancer.

Imaging technology is also used after the initial diagnosis and throughout the course of treatment to reevaluate the tumor size and identify possible metastases.

Innovations in Adjuvant Care

Using a combination of chemotherapy and/or radiation before or after surgery is a common practice in the treatment of bone cancer. Our pediatric and medical oncologists developed standard strategies for chemotherapy for this kind of cancer. For example, a type of treatment called induction chemotherapy -- often administered before surgery to reduce the size of the tumor to make surgery more effective -- was pioneered at Memorial Sloan-Kettering.

Radiation therapy is also often used in combination with surgery or chemotherapy to destroy tumors or to reduce the size of the tumor. Radiation therapy may also be used to kill remaining cancer cells after surgery, or treat tumors that cannot be surgically removed.

Research is also under way at Memorial Sloan-Kettering to evaluate the application of radiation directly to the bone during surgery (intraoperative radiation therapy). We are also evaluating new ways to apply radiation therapy directly to bone cancers. This novel form of radiation therapy -- called intensity-modulated radiation therapy (IMRT) -- targets tumors so efficiently that it leaves healthy tissue unharmed.

Applying Scientific Discoveries to Medical Practice

Memorial Sloan-Kettering investigators are scrutinizing the genetic changes that cause and define bone cancer, and determining why some bone cancers respond more readily to treatment than others. Such knowledge may give doctors the information they need to select the best course of treatment for a patient.

Find a Clinical Trial
Find a Clinical Trial
Find out about new research studies for bone cancer

Investigational Approaches

New approaches to treating bone cancer at Memorial Sloan-Kettering are constantly being developed to improve treatment options. Research protocols involving the study of investigational approaches are sometimes offered to eligible patients through the clinical trial process. Clinical trials are designed to advance the current standards of care.

Our current clinical research is focused on identifying new agents to use to treat the most common of these tumors, specifically osteosarcoma, Ewing's sarcoma, chondrosarcoma, and malignant fibrous histiocytoma of bone. We are also examining both standard chemotherapy agents as well as newer, less toxic "targeted" agents.

For example, clinical trials are now underway to assess potentially more effective chemotherapy drugs for different kinds of bone cancer. One study will examine and evaluate the use of standard chemotherapy agents -- gemcitabine and docetaxel -- in patients with osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Another study is examining the effects of a biological therapy called sorafenib (which is a type of tyrosine kinase, or protein enzyme) in patients with soft tissue and bone sarcoma.

Another study is assessing the use of trastuzumab (Herceptin®), a drug currently used to treat advanced breast cancer. Trastuzumab targets cancer cells that overproduce a protein called HER-2, which is found in excess in osteosarcoma tumors that recur following treatment.

A clinical study is now underway to evaluate the safety and effectiveness of a treatment regimen called myeloablative therapy for patients with Ewing's sarcoma. The treatment includes a combination of several drugs followed by hematopoietic stem cell transplantation.


Last Updated: Feb. 8, 2006
PrintEmail This Page